The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylysalicylic acid with the statin, for use in the prevention or treatment of cardiovascular diseases.本發明係關於一種藥物組成物,該藥物組成物包括HMG-CoA還原酶抑制劑(特定而言,士他汀(statin))及乙醯水楊酸,此包括之方式可最小化乙醯水楊酸與該士他汀之相互作用,該藥物組成物用於預防或治療心血管疾病。